261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands
Neuromuscular Disorders · 2023
DOI: 10.1016/j.nmd.2023.09.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2023. Verfasst von Laurent Servais und 5 weiteren Autor:innen. Beteiligte Einrichtung: MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; Division of Child Neurology, Centre de R…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Neuromuscular Diseases. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Adeno-associated virus (AAV) gene therapies are demonstrating much promise in the area of neuromuscular disorders. There are now therapies in clinical trials or real-world use for several disorders including spinal muscular atrophy and Duchenne muscular dystrophy. However, there have been several concerning reports of serious adverse events, including deaths. Reporting and monitoring of these is not consistent between trials. Therefore, a group of clinicians, investigators, industry and patient representatives met the weekend of 17th-19th June 2022 to discuss safety issues arising from the use of these therapies. The group shared information on safety events across a spectrum of AAV gene therapy products, both in clinical trials and commercial use. Patterns of serious adverse events were identified and the group discussed methods of identification and management of these as well as new ways of improving information sharing across industry in order to improve the safety of these promising treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; Division of Child Neurology, Centre de Référence des Maladies Neuromusculaires, Department of Pediatrics, Univ…
- MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
- Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
- National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.
- UCL Great Ormond Street Institute of Child Health, The Dubowitz Neuromuscular Centre, London, UK; National Institute for Health Research, Great Ormond Street Institute of Child Health Biomedical Research Centre, Univers…
Zitieren
APA
Servais, L., Horton, R., Saade, D., Bonnemann, C., Muntoni, F., & 261st ENMC workshop study group (2023). 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2023.09.008
Vancouver
Servais L, Horton R, Saade D, Bonnemann C, Muntoni F, 261st ENMC workshop study group. 261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands. Neuromuscular Disorders. 2023. doi:10.1016/j.nmd.2023.09.008
BibTeX
@article{Servais2023,
author = {Servais, Laurent and Horton, Rebecca and Saade, Dimah and Bonnemann, Carsten and Muntoni, Francesco and 261st ENMC workshop study group, 261st ENMC workshop study group},
title = {261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands},
journal = {Neuromuscular Disorders},
year = {2023},
doi = {10.1016/j.nmd.2023.09.008}
}
EUVIMED